Definition of a Threshold for the Plasma Aβ42/Aβ40 Ratio Measured by Single-Molecule Array to Predict the Amyloid Status of Individuals without Dementia

• Published in: International journal of molecular sciences Vol. 25; no. 2; p. 1173
• Main Authors: Colmant, Lise, Boyer, Emilien, Gerard, Thomas, Sleegers, Kristel, Lhommel, Renaud, Ivanoiu, Adrian, Lefèvre, Philippe, Kienlen-Campard, Pascal, Hanseeuw, Bernard
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.01.2024
• Subjects: Advertising executives; Alzheimer Disease - diagnosis; Alzheimer's disease; Amyloid beta-Peptides; Amyloidogenic Proteins; Antigens; Biomarkers; Blood tests; Brain; Cognitive ability; Dementia; Enzymes; Gender; Humans; Medical research; Medicine, Experimental; Pathology; Peptides; PET imaging; Plaque, Amyloid; Plasma; Positron-Emission Tomography; Belgium; Taiwan; plasma amyloid; amyloid prediction; Alzheimer’s disease; biomarkers; SIMOA; plasma Aβ42/Aβ40 ratio; Alzheimer’s disease screening
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms25021173

Alzheimer’s disease (AD) is characterized by amyloid beta (Aβ) plaques and hyperphosphorylated tau in the brain. Aβ plaques precede cognitive impairments and can be detected through amyloid-positron emission tomography (PET) or in cerebrospinal fluid (CSF). Assessing the plasma Aβ42/Aβ40 ratio seems promising for non-invasive and cost-effective detection of brain Aβ accumulation. This approach involves some challenges, including the accuracy of blood-based biomarker measurements and the establishment of clear, standardized thresholds to categorize the risk of developing brain amyloid pathology. Plasma Aβ42/Aβ40 ratio was measured in 277 volunteers without dementia, 70 AD patients and 18 non-AD patients using single-molecule array. Patients (n = 88) and some volunteers (n = 66) were subject to evaluation of amyloid status by CSF Aβ quantification or PET analysis. Thresholds of plasma Aβ42/Aβ40 ratio were determined based on a Gaussian mixture model, a decision tree, and the Youden’s index. The 0.0472 threshold, the one with the highest sensitivity, was retained for general population without dementia screening, and the 0.0450 threshold was retained for research and clinical trials recruitment, aiming to minimize the need for CSF or PET analyses to identify amyloid-positive individuals. These findings offer a promising step towards a cost-effective method for identifying individuals at risk of developing AD.